As a tumor suppressor FBLN1 levels are downregulated in epithelial cancers including melanoma (Wu et al., 2014), squamous cell carcinoma (Zhang et al., 2013), renal cell carcinoma (Xiao et al., 2013), hepatocellular carcinoma (Kanda et al., 2011), gastric carcinoma (Cheng et al., 2008), prostate carcinoma (Wlazlinski et al., 2007), colorectal carcinoma (Pesson et al., 2014), and lung adenocarcinoma (LUAD) (Cui et al., 2015). This evidence concerns the gene FBLN1 and neoplasm.